Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drug reimbursement

Roche Basel Switzerland

China backs use of Roche’s Actemra for coronavirus

Anti-inflammatory drug will be used in patients with lung complications

- PMLiVE

India’s export curbs raise fears of global drug shortages

Decision comes amid increased concerns over coronavirus outbreak

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

- PMLiVE

Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

Solidifies immunotherapy drug's dominance in the setting

- PMLiVE

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

Gained conditional approval in China in November

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

Continued expansion for next-generation immunology drug

- PMLiVE

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

Met key primary and secondary trial endpoints

- PMLiVE

China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta

- PMLiVE

Merck’s Keytruda picks up third approval for NSCLC in China

New indication as a first-line treatment in combination with chemotherapy

- PMLiVE

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

Updated draft evidence report maintains the benefit is small with higher price tag

Novartis day

Novartis changes focus in Shanghai from early research to drug development

Swiss pharma switches focus of $1bn R&D institute

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links